IL299915A - Methods for assembling cleaning particles - Google Patents

Methods for assembling cleaning particles

Info

Publication number
IL299915A
IL299915A IL299915A IL29991523A IL299915A IL 299915 A IL299915 A IL 299915A IL 299915 A IL299915 A IL 299915A IL 29991523 A IL29991523 A IL 29991523A IL 299915 A IL299915 A IL 299915A
Authority
IL
Israel
Prior art keywords
particle
soluble
agent
subparticle
receptor
Prior art date
Application number
IL299915A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nanotics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotics Llc filed Critical Nanotics Llc
Publication of IL299915A publication Critical patent/IL299915A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Composite Materials (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL299915A 2017-01-04 2018-01-04 Methods for assembling cleaning particles IL299915A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762442376P 2017-01-04 2017-01-04
US201762442327P 2017-01-04 2017-01-04
PCT/US2018/012414 WO2018129207A1 (en) 2017-01-04 2018-01-04 Methods for assembling scavenging particles

Publications (1)

Publication Number Publication Date
IL299915A true IL299915A (en) 2023-03-01

Family

ID=62791211

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299915A IL299915A (en) 2017-01-04 2018-01-04 Methods for assembling cleaning particles
IL267765A IL267765B2 (en) 2017-01-04 2019-07-01 Methods for assembling cleaning particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL267765A IL267765B2 (en) 2017-01-04 2019-07-01 Methods for assembling cleaning particles

Country Status (5)

Country Link
US (3) US11065345B2 (de)
EP (1) EP3565604A4 (de)
JP (2) JP2020504177A (de)
IL (2) IL299915A (de)
WO (1) WO2018129207A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035898B1 (ru) 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
EP3328362A4 (de) 2015-07-29 2019-03-06 Nanotics, LLC Modulare zusammensetzungen zur abscheidung von löslichen biomolekülen und zugehörige verfahren
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
EP3596108A4 (de) 2017-03-15 2020-12-23 Pandion Operations, Inc. Gezielte immuntoleranz
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3846853A1 (de) 2018-09-04 2021-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Viruzide nanopartikel und verwendung davon gegen influenzavirus
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP3986429A4 (de) 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. Plattformen, zusammensetzungen und verfahren zur verabreichung von therapeutika
JP2023512562A (ja) 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
EP4107187A4 (de) 2020-02-21 2024-07-03 Pandion Operations, Inc. Gewebegezielte immuntoleranz mit einem cd39-effektor
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
EP4179118A4 (de) * 2020-08-19 2024-10-23 Ohio State Innovation Foundation Hochempfindliche plattform zur charakterisierung extrazellulärer vesikulärer biomarker für krebsimmuntherapie
US20230391863A1 (en) * 2020-10-23 2023-12-07 Hq Han Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
US11939213B2 (en) 2020-12-21 2024-03-26 Raytheon Company Programmable structural building blocks
KR102266385B1 (ko) * 2021-01-22 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 그 제조방법 및 이를 포함하는 동결건조체 및 필러용 주사제
US20250290844A1 (en) * 2021-05-10 2025-09-18 The Regents Of The University Of California Methods of using shaped particles in flow cytometers for assays on b cells and t cells
WO2024086510A1 (en) * 2022-10-17 2024-04-25 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compounds and use thereof
AU2024305445A1 (en) * 2023-06-14 2026-01-08 Nautilus Subsidiary, Inc. Making and using structured nucleic acid particles
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
WO2025079662A1 (ja) * 2023-10-10 2025-04-17 国立大学法人京都大学 生体分子間相互作用の新規解析法
WO2025240771A1 (en) * 2024-05-16 2025-11-20 Curadel Surgical Innovations, Inc. Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof
CN119367594B (zh) * 2024-12-30 2025-04-08 山东大学 一种多孔钛合金植入体双层缓释系统及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
EP1227843B1 (de) 1999-11-10 2009-10-14 BioPheresis Technologies, Inc. Verfahren und system zur entfernung von zytokininhibitoren in patienten
EP1174129A1 (de) 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Verwendung eines Matrix-Metalloproteinase-Inhibitors zur Behandlung von Krebs
DE10144251A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Vorrichtung für die gerichtete Immobilisierung von Proteinen
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
EP2436676A1 (de) 2002-06-12 2012-04-04 Symphony Evolution, Inc. Humane Adam-10-Hemmer
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US7297298B2 (en) 2002-12-25 2007-11-20 Fujifilm Corporation Nano-particles and process for producing nano-particles
WO2004071641A2 (en) 2003-02-10 2004-08-26 Pointilliste, Inc. Self-assembling arrays and uses thereof
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
JP2008511340A (ja) 2004-04-30 2008-04-17 バイオフェレシス テクノロジーズ， インコーポレイテッド 患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
JP2008507529A (ja) 2004-07-22 2008-03-13 アーリー ディテクション， エルエルシー 抗サイトカインレセプター抗体を用いる診断のための方法
CN101123990A (zh) 2004-10-01 2008-02-13 Mida科技有限公司 包含抗原和佐剂的纳米颗粒，和免疫原性结构
WO2006086428A2 (en) 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Particles for inactivating toxins
US20110097277A1 (en) 2005-08-25 2011-04-28 University Of Washington Particles coated with zwitterionic polymers
FR2895289B1 (fr) 2005-12-23 2009-08-21 Centre Nat Rech Scient Synthese de particules dans des structures dendritiques en milieux fluides supercritiques
WO2007095158A2 (en) 2006-02-13 2007-08-23 Advanced Materials Technology, Inc. Process for preparing substrates with porous surface
EP2056794A4 (de) 2006-08-08 2012-12-26 Univ Texas Mehrstufige verabreichung von wirkstoffen
US20080075690A1 (en) 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
WO2008041774A1 (en) 2006-10-02 2008-04-10 National Institute For Materials Science Sustained-release preparation having bone conduction ability
WO2008127515A1 (en) 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
EP2033660A1 (de) 2007-09-05 2009-03-11 Freie Universität Berlin Funktionalisierte Nanopartikel zur Hemmung Selectin-vermittelter Zelladhäsion
US8586096B2 (en) 2007-10-01 2013-11-19 The Curators Of The University Of Missouri Soy or lentil stabilized gold nanoparticles and method for making same
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN101951890A (zh) 2007-12-13 2011-01-19 阿杜罗生物技术公司 配体缀合的热疗感受器及其制备方法
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
US9333163B2 (en) 2008-10-06 2016-05-10 Massachusetts Institute Of Technology Particles with multiple functionalized surface domains
MX2011007532A (es) 2009-01-15 2011-11-04 Univ Texas Estructuras porosas con cinetica de biodegradacion modificada.
US20120108787A1 (en) * 2009-02-26 2012-05-03 Nubiome, Inc. Immobilization Particles for Removal of Microorganisms and/or Chemicals
WO2010111517A1 (en) 2009-03-25 2010-09-30 Northeastern University Stable polyelectrolyte coated nanoparticles
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
IN2012DN05099A (de) * 2009-12-16 2015-10-09 Brigham & Womens Hospital
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
US20120141797A1 (en) 2010-04-21 2012-06-07 Brookhaven Science Associates, Llc Zwitterion-Linker Coatings for Nano-objects in Solutions of Multivalent Counterions
ES2628351T3 (es) 2010-10-13 2017-08-02 Pharma Diagnostics Nv Método para recubrir nanopartículas
WO2012163544A1 (en) 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
EP2714017B1 (de) 2011-06-02 2018-08-01 The Regents of The University of California In membranen verkapselte nanopartikel und verwendungsverfahren dafür
CA2883080A1 (en) * 2011-08-26 2013-03-07 Vecoy Nanomedicines Ltd. Pathogen and substance traps
WO2013029278A1 (en) 2011-09-02 2013-03-07 National Center For Nanoscience And Technology A method for preparing functionalized silicon nanoparticles
WO2013095736A2 (en) 2011-09-27 2013-06-27 The Methodist Hospital Research Institute Gold-in-silicon nanoassembly for thermal therapy and methods of use
CA2938661A1 (en) * 2011-10-21 2013-04-25 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US20130337070A1 (en) 2012-05-25 2013-12-19 University Of Central Florida Research Foundation Inc. Coated Nanoparticle Therapy for Skin Cancer
WO2013179143A2 (en) 2012-06-01 2013-12-05 Biopheresis Technologies, Inc. Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors
US10842749B2 (en) 2012-06-12 2020-11-24 The Methodist Hospital Research Institute Compositions and methods of treating therapy resistant cancer and uses thereof
KR102069538B1 (ko) * 2012-07-12 2020-03-23 삼성전자주식회사 멀티미디어 요소의 배치를 위한 마크업을 구성하는 방법
ITRM20120350A1 (it) * 2012-07-19 2014-01-20 Univ Degli Studi Milano Nanocostrutti con attività farmacologica.
US10543278B2 (en) 2012-09-12 2020-01-28 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
US20140220133A1 (en) 2012-11-28 2014-08-07 Cytimmune Sciences, Inc. Nanotechnology Based Medicine for Biodefense
EP2958595A1 (de) * 2013-02-20 2015-12-30 INSERM - Institut National de la Santé et de la Recherche Médicale Aktivierung von inkt-zellen
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
US20150112842A1 (en) 2013-10-21 2015-04-23 Insurance Auto Auctions, Inc. Parts exchange method and apparatus
EP3097420A4 (de) 2014-01-24 2018-01-17 Ntercept, LLC Verfahren und zusammensetzungen für immun-dis-inhibition
EA035898B1 (ru) * 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
CN114129737A (zh) 2015-06-30 2022-03-04 纳米提克斯有限责任公司 与清除颗粒相关的组合物和方法
EP3328362A4 (de) 2015-07-29 2019-03-06 Nanotics, LLC Modulare zusammensetzungen zur abscheidung von löslichen biomolekülen und zugehörige verfahren
US20170056327A1 (en) 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
WO2018129188A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles

Also Published As

Publication number Publication date
IL267765B1 (en) 2023-03-01
US20240269319A1 (en) 2024-08-15
JP2020504177A (ja) 2020-02-06
US20200179531A1 (en) 2020-06-11
US11065345B2 (en) 2021-07-20
IL267765A (en) 2019-09-26
IL267765B2 (en) 2023-07-01
US20220133905A1 (en) 2022-05-05
EP3565604A4 (de) 2020-09-09
JP2023075293A (ja) 2023-05-30
US12083186B2 (en) 2024-09-10
EP3565604A1 (de) 2019-11-13
WO2018129207A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
US12083186B2 (en) Methods for assembling scavenging particles
US10653790B2 (en) Compositions and methods related to scavenger particles
AU2022200233B2 (en) Compositions and methods related to scavenger particles
WO2018129188A1 (en) Methods for assembling scavenging particles
WO2017176762A1 (en) Particles comprising subparticles or nucleic acid scaffolds
HK40070318A (en) Modular compositions for scavenging soluble biomolecules and methods related thereto
EA042292B1 (ru) Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы
HK40100534A (zh) 与清除颗粒相关的组合物和方法
HK40100533A (zh) 与清除颗粒相关的组合物和方法
BR112017028315B1 (pt) Partículas de sequestrante, composições farmacêuticas e seus usos